Dorsomorphin (Compound C): Precision AMPK Inhibition for ...

2026-02-27

Dorsomorphin (Compound C): Precision AMPK Inhibition for Pathway Dissection

Principle Overview: The Dual Role of Dorsomorphin in Cell Signaling

Dorsomorphin (Compound C) is a highly selective, reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK), with a Ki of 109 nM, and a potent blocker of bone morphogenetic protein (BMP) signaling via Smad 1/5/8 phosphorylation inhibition. Its unique profile allows researchers to interrogate both metabolic and differentiation pathways with precision, making it indispensable in studies spanning autophagy regulation, cancer metabolism, neural stem cell differentiation, and iron metabolism modulation. Supplied by APExBIO, Dorsomorphin (Compound C) (SKU B3252) is widely adopted for inhibition of AMPK activity in hepatocytes, suppression of ACC phosphorylation, and BMP4-induced SMAD phosphorylation inhibition, providing a robust platform for dissecting the AMPK and BMP/Smad signaling pathways in vitro and in vivo.

Step-by-Step Experimental Workflow and Protocol Enhancements

1. Compound Preparation

Solubilization: Dorsomorphin is insoluble in water and ethanol; dissolve in DMSO (≥8.49 mg/mL) using gentle warming and ultrasonic treatment for optimal clarity. Avoid prolonged sonication to prevent compound degradation.
Aliquoting and Storage: Prepare single-use aliquots and store at -20°C. Use solutions promptly, as long-term storage can reduce potency.

2. Cell Culture Applications

AMPK Inhibition in Hepatocytes/HeLa Cells: Treat cells with Dorsomorphin at 4–40 μM for 1–24 hours, depending on endpoint (e.g., phosphorylation status, metabolic flux, autophagy markers). For ACC phosphorylation inhibition, 80% reduction is achievable at standard concentrations.
BMP4-Induced SMAD Phosphorylation Inhibition: Pre-treat cells with 2–10 μM Dorsomorphin for 30–60 minutes prior to BMP4 stimulation. The IC₅₀ for SMAD inhibition is 0.47 μM, facilitating sensitive pathway modulation even at low doses.

3. Animal Model Applications

Iron Metabolism and Hepcidin Regulation: For in vivo modulation, administer 10 mg/kg Dorsomorphin via intraperitoneal injection. Monitor hepatic hepcidin mRNA and serum iron levels 6–48 hours post-administration. Efficacy is evidenced by decreased hepcidin expression and increased serum iron.
Developmental and Differentiation Studies: In zebrafish, microinject 1–10 μM Dorsomorphin to induce dorsalization phenotypes or modulate neural induction, tracking BMP/Smad signaling outputs.

4. Enhanced Protocol Tips

When targeting autophagy regulation or mitophagy (e.g., LC3-II/I ratio, PINK1/Parkin pathway), pre-validate Dorsomorphin sensitivity in your specific cell line by titrating from low nanomolar to mid-micromolar concentrations. This is crucial for workflow reproducibility and interpretation, as highlighted in recent studies on metabolic disease models (see Ren et al., 2025).

Advanced Applications and Comparative Advantages

Cancer Research and Immunometabolism

Dorsomorphin’s high selectivity for AMPK over kinases such as PKA, PKC, and JAK3 enables targeted investigation of cancer cell metabolism and autophagy. Its role as an ATP-competitive AMPK inhibitor is pivotal for dissecting the AMPK signaling pathway in tumor energetics, metabolic reprogramming, and cytotoxicity assays. For example, in metabolic disease and immunometabolic studies, Dorsomorphin has been used to clarify how AMPK modulation intersects with autophagy and macrophage polarization (GSK3B article), complementing its established applications in metabolic flux analysis.

Stem Cell and Neural Differentiation

Dorsomorphin (Compound C) is a cornerstone reagent for neural induction of human embryonic stem cells by inhibiting BMP/Smad signaling, facilitating controlled neural lineage commitment. This dual-pathway inhibition is instrumental for protocol optimization in stem cell research, supporting reproducibility and scalability (Compound-56 article), and extending the findings of BMP pathway modulation in early development.

Iron Metabolism and Hepatic Studies

By inhibiting BMP-driven hepcidin transcription, Dorsomorphin allows researchers to manipulate systemic iron homeostasis in animal models. This application not only advances iron metabolism research but also provides a platform for exploring hepcidin-targeted therapies, as detailed in comparative guides (TGF-β article), which contrast Dorsomorphin’s workflow compatibility and selectivity with alternative small molecule inhibitors.

Autophagy and Mitophagy Regulation

Recent studies, including the reference by Ren et al. (2025), underscore Dorsomorphin’s critical role in dissecting autophagy regulation via the AMPK/PINK1/Parkin axis. The authors demonstrated that Lycium barbarum polysaccharide’s beneficial effects on skeletal muscle atrophy were negated by AMPK inhibition with Dorsomorphin, directly linking its use to mitochondrial quality control and sarcopenic obesity models. This positions Dorsomorphin as an essential tool for validating pathway specificity in metabolic and aging research.

Troubleshooting & Optimization Tips for Dorsomorphin Use

Solubility and Compound Integrity: Always use high-grade DMSO and filter-sterilize solutions for cell applications. If precipitation occurs, gently rewarm and briefly sonicate; avoid repeated freeze-thaw cycles.
Cytotoxicity and Off-Target Effects: Include a DMSO-only control to account for solvent effects. For sensitive primary cells, start at the lowest recommended dose and monitor cell viability (e.g., MTT or CellTiter-Glo assays).
Pathway Confirmation: Validate AMPK inhibition by assessing ACC phosphorylation; an 80% decrease indicates robust pathway targeting. For BMP/Smad inhibition, confirm via p-Smad 1/5/8 Western blotting. For autophagy endpoints, measure LC3-II/I ratio and p62 turnover.
Batch-to-Batch Consistency: Source Dorsomorphin (Compound C) directly from APExBIO to minimize variability. Cross-reference lot performance with published protocols (PLX3397 article) to ensure reproducible results.
Timing and Exposure: For transient pathway dissection, limit exposure to 1–2 hours. For sustained inhibition (e.g., in metabolic flux or differentiation assays), optimize duration based on endpoint kinetics and cell type sensitivity.

Future Outlook: Expanding the Impact of Dorsomorphin in Research

The landscape of AMPK and BMP/Smad pathway research is rapidly evolving. As new disease models, such as sarcopenic obesity and metabolic aging, demand greater mechanistic clarity, Dorsomorphin (Compound C) will continue to serve as a gold-standard inhibitor for pathway dissection. Its proven utility in combination with genetic approaches (e.g., siRNA knockdown) and emerging pharmacological modulators opens new avenues for high-content screening, regenerative medicine, and metabolic disease intervention. Ongoing integration with omics platforms and live-cell imaging will further enhance the resolution of autophagy and metabolic flux studies, reinforcing the value of Dorsomorphin supplied by APExBIO in cutting-edge biomedical research.